Decoy Therapeutics Inc. Common Stock DCOY
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $30.00 (+679.2% upside)
Key Stats
- Today's Range
- $3.75 – $4.71
- 50-Day Range
- $2.18 – $7.61
- 52-Week Range
- $2.18 – $16.92
- Volume
- 26.77 million shs
- Average Volume
- 4.43 million shs
- Market Cap
- $2.52 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 163.62%
- Days to Cover
- 1.00
About Decoy Therapeutics Inc. Common Stock
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
Related Stocks
Compare head-to-head: DCOY vs LLY·DCOY vs JNJ·DCOY vs ABBV·DCOY vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.